ArticleJournal of global health2026
Global prevalence trends and predictions of Hodgkin lymphoma from 1990 to 2021: age-period-cohort analysis and transnational inequality.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hodgkin lymphoma (HL) is a highly curable malignancy with distinctive aetiological subtypes. Given recent therapeutic advances and demographic changes, an up-to-date assessment of the global HL burden is needed to inform evidence-based resource allocation and health policy planning. This study described the global prevalence trend of HL and analysed its age cohort and transnational inequality. Methods: We used data from the Global Burden of Disease 2021 study (204 countries/territories). We analysed age-standardised rates (ASRs) for incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) from 1990 to 2021. An autoregressive integrated moving average (ARIMA) model projected incidence trends to 2050. We used the age-period-cohort (APC) analysis to separate the effects of age, period, and cohort on HL burden. We assessed transnational inequality with the slope index of inequality and the concentration index. All estimates are reported with 95% uncertainty intervals (UI). Results: In 2021, an estimated 65,182 (95% UI = 53,167, 77,143) new HL cases occurred globally. Substantial geographic disparities were observed in ASRs per 100,000 population: prevalence 4.42 (95% UI = 3.75, 5.09), incidence 0.79 (95% UI = 0.64, 0.94), mortality 0.34 (95% UI = 0.25, 0.43), and DALYs 14.82 (95% UI = 10.43, 18.96). The global age-standardised incidence rate (ASIR) declined slightly (estimated annual percentage change = -1.10%; 95% confidence interval (CI) = -1.16, 1.05) from 1990 to 2021, yet absolute incident cases increased by 19.23% (95% CI = 14.14, 22.44), driven by population growth and ageing. We found that HL risk peaked among young (25-29 years) and older adults (65-69 years), with steady declines in relative risk across successive periods and birth cohorts. The burden consistently skewed towards males and high sociodemographic index (SDI) regions. Projections indicated a stable ASIR but a rising prevalence through 2050, alongside continued declines in mortality and DALY rates. Conclusions: We found that the global HL burden is characterised by stable ASIR but growing absolute case numbers, with a disproportionate impact on males and high-SDI countries. These trends, reflecting demographic shifts and therapeutic advances, underscore the necessity for robust diagnostic pathways and multidisciplinary, risk-adapted care models to manage the increasing population of HL survivors effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.